In Vitro and in Vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5397-5400

  De Léséleuc, Louis ^a   Harris, Greg ^a   KuoLee, Rhonda ^a   Chen, Wangxue ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' BIPYRIDINE; CHELATING AGENT; GALLIUM NITRATE; TRANSFERRIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIOSTASIS; CONTROLLED STUDY; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; IRON METABOLISM; IRON RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

2,2'-DIPYRIDYL; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; GALLIUM; IRON CHELATING AGENTS; MICE; TRANSFERRIN;

EID: 84866326661     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00778-12     Document Type: Article

References (14)

1. Bernstein LR. 1998. Mechanisms of therapeutic activity for gallium. Pharmacol. Rev. 50:665-682. (Pubitemid 29028814)
2. Bernstein LR, Tanner T, Godfrey C, Noll B. 2000. Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Met. Based Drugs 7:33-47. (Pubitemid 30153561)
3. Boelaert JR, et al. 1993. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin. Invest. 91:1979-1986. (Pubitemid 23141469)
4. Chitambar CR. Medical applications and toxicities of gallium compounds. Int. J. Environ. Res. Public Health 7:2337-2361.
5. DeLeon K, et al. 2009. Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob. Agents Chemother. 53:1331-1337.
6. Fernandes SS, et al. 2010. Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium. Microbes Infect. 12:287-294.
7. Ibrahim AS, et al. 2007. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Invest. 117:2649-2657. (Pubitemid 47494365)
8. Ibrahim AS, et al. 2011. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob. Agents Chemother. 55:1768-1770.
9. Johnson EE, Wessling-Resnick M. 2012. Iron metabolism and the innate immune response to infection. Microbes Infect. 14:207-216.
10. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. 1997. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob. Agents Chemother. 41:345-351. (Pubitemid 27111029)
11. Kontoghiorghes GJ. 2006. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 30:183-200.
12. Li S, Crooks PA, Wei X, de Leon J. 2004. Toxicity of dipyridyl compounds and related compounds. Crit. Rev. Toxicol. 34:447-460. (Pubitemid 39350536)
13. Renckens R, et al. 2006. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii pneumonia. J. Infect. Dis. 193:187-195.
14. van Faassen H, et al. 2007. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect. Immun. 75:5597-5608.